NCT05106101

L-glutamine Treatment in Patients With Diverticulosis

A Pilot/Phase 1, Interventional, Open-label, Multi-center Study to Assess the Safety and Efficacy of L-glutamine Treatment in Patients With Diverticulosis

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Emmaus Medical, Inc. · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is evaluate the safety and efficacy of L-glutamine as a treatment for patients with diverticulosis.

Detailed description

After being informed about the study and potential risks, all patients giving written informed consent will undergo a 4 weeks screening period to determine eligibility for study entry. At Week 0, patients who meet eligibility requirements will be given L-glutamine (15 grams, twice daily)

Conditions

• Diverticulosis, Colonic

Interventions

Type	Name	Description
DRUG	L-glutamine	L-glutamine oral powder in 5 gram packet

Timeline

• Start date: 2019-07-19
• Primary completion: 2022-12-30
• Completion: 2022-12-30
• First posted: 2021-11-03
• Last updated: 2023-02-16

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study